Ozempic and Wegovy have become widely used for weight loss and diabetes management across Canada. While these medications deliver real results, their high cost has put significant pressure on employee benefit plans, especially for small and mid-sized employers.
Recent updates suggest that may soon change. The patent and data exclusivity protections for semaglutide — the active ingredient in both Ozempic and Wegovy — are set to expire in January 2026 in Canada. Once this happens, generic versions could enter the market, driving down prices.
When a drug comes off patent, other pharmaceutical companies can apply to produce generic equivalents. These generics must meet strict Health Canada standards for safety, quality, and effectiveness, but they typically sell at much lower prices than the original brand.
Industry reports suggest that once generic semaglutide becomes available, prices could drop by 30–50%. The actual reduction will depend on how quickly generic manufacturers receive approval and how insurers update their drug formularies.
In the last few years, high-cost specialty drugs like Ozempic have been major contributors to increasing health claims and higher renewal rates. A single employee using these medications can significantly affect overall plan costs.
If generics become available in 2026, many plan sponsors could see stabilized renewals and reduced drug spending. This could make benefit plans more sustainable and affordable while maintaining important coverage for employees.
Insurers will play a key role. Each carrier will decide when to include generics on their approved list and how savings are passed along to employers.
Review renewal reports for Ozempic or other high-cost drug claims.
Ask your benefits advisor when your insurer expects to add generic semaglutide.
Evaluate your plan design to ensure it balances employee access with long-term cost control.
The potential arrival of Ozempic generics in Canada as early as 2026 could be good news for both employers and employees. It’s a reminder of how quickly drug costs and plan sustainability can shift — and why ongoing benefits reviews matter.
If you’d like to discuss how specialty drugs like Ozempic are affecting your plan or explore strategies to keep your employee benefits program affordable, contact Nick Godfrey Insurance for a personalized review.